NCT03230526View on ClinicalTrials.gov

Identification of a Biomarker Predictive of Evolution of Parkinson Disease

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

April 16, 2018

Primary Completion Date

May 6, 2024

Study Completion Date

May 6, 2024

Conditions
Parkinson Disease
Interventions
DRUG

[18F]DPA-714 PET scan

"One PET scan using \[18F\]DPA-714 is done at M2 between two \[123I\]FP-CIT scan (DaTscan) done at M1 and M23.~Neuropsychological assessment is done at M0, M18 and M24"

Trial Locations (4)

Unknown

CHU de Nantes, Nantes

Centre Eugène Marquis, Rennes

CHU de Rennes, Rennes

CHU de Tours, Tours

All Listed Sponsors
lead

Nantes University Hospital

OTHER

NCT03230526 - Identification of a Biomarker Predictive of Evolution of Parkinson Disease | Biotech Hunter | Biotech Hunter